Joaquina Baranda

Research

Overview

Joaquina Baranda, MD, focuses her research on drug development and early therapeutics through investigator initiated trials, national and industry sponsored trials. She has served as the principal investigator in phase I, II and III clinical trials in gastrointestinal cancers and later as an early phase investigator in different malignancies. Dr. Baranda is one of the leaders in translational clinical trial development at KU Cancer Center and nationally through the Southwest Oncology Group (now known as SWOG) with active roles in the GI working group.

Dr. Baranda leads the Early Phase research unit at KU Cancer Center with the goal of increasing patient access to novel agents and developing translational investigations with biomarker development leading to precision medicine. She is the co-chair of the KU Cancer Center Investigator Initiated Trial Executive Committee. For many years she served as Chair of KU Cancer Center’s Cancer Program Education Committee, the Multidisciplinary Tumor Conference and was leader of GI oncology.

• A PHASE 1 2, OPEN-LABEL, MUL TICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH BEMPEGALDESLEUKIN {NKTR-214) AND IN COMBINATION WITH BEMPEGALDESLEUKIN, Nektar Therapeutics, PI

• Bazhenova, Lyudmila, Gold, Philip., J, Harvey, R., Donald, Spira, Alexander., I, Nemunaitis, John, Baranda, Joaquina., C, Gadgeel, Shirish. 2017. A Phase 1b study of PEGPH20 plus pembrolizumab in patients with selected hyaluronan-high solid tumors.
• Petrylak, D, Smith, D, Flaig, T, Zhang, J, Sridhar, S, Ruether, J, Plimack, E, Merchan, J, Quinn, D, Kilari, D, Srinivas, S, Baranda, J, Lang, J, Milowsky, M, Galsky, M, Spira, A, Gartner, E, Wu, C, Melhem-Bertrandt, A, Rosenberg, J. 2017. Enfortumab Vedotin (EV) in Patients (Pts) with Metastatic Urothelial Carcinoma (mUC) with Prior Checkpoint Inhibitor (CPI) Failure: A Prospective Cohort of an Ongoing Phase 1 Study
• Rischin, D, Gil-Martin, M, Gonazlez-Martin, A, Brana, I, Hou, J., Y, Cho, D, Falchook, G., S, Formenti, S, Jabbour, S, Moore, K, Naing, A, Papadopoulos, K., P, Baranda, J, Weise, A, Ury, M., G, Feng, M, Li, J, Lowry, I, Mathias, M. 2018. Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts. Annals of Oncology, 29 (S8), 166.
• Kasi, Anup, Chalise, Prabhakar, Williamson, Stephen ., K, Baranda, Joaquina., Celebre, Sun, Weijing, Al-Rajabi, Raed., Moh'd Taiseer, Saeed, Anwaar, Kumer, Sean, Schmitt, Timothy, Foster, Carolyn, Pessetto, Ziyan., Y, Witek, Malgorzata., A, Soper, Steven., A, Godwin, Andrew., K. 2019. Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial. ASCO Pubs.
• Telfah, Mohammad, Iwakuma, tomoo, Bur, Andres, Shnayder, Lisa, Tsue, Terry, Al-Kasspooles, Mazin, Ashcraft, John, Martin, Benjamin, Al-Rajabi, Raed., Moh'd Taiseer, Kasi, Anup, Khan, Qamar., J, Lin, Tara., L, Saeed, Anwaar, Williamson, Stephen., K, Chalise, Prabhakar, Godwin, Andrew., K, Reed, Greg, Thomas, Sufi, Komiya, Takefumi, Baranda, Joaquina., Celebre. 2019. A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies. ASCO Pubs.
• Balmaceda, Nicole, Mouw, T, Abhyankar, Sunil, Male, Heather, Woodroof, J, Baranda, Joaquina. 2019. Hematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors. European Society of Medical Oncology (ESMO).
• Mohyuddin, Ghulam., Rehman, Baranda, Joaquina., C, Bur, Andres, Shnayder, Lisa, Kakarala, Kiran, Tsue, Terry, Neupane, Prakash, Gan, Gregory, Mammen, Joshua, Aires, Daniel, Thomas, Sufi, Williamson, Stephen., K, Lakis, Nelli, Madan, Rashna, Chalise, Prabhakar, Weir, Scott, Godwin, Andrew, Reed, Greg, Berkland, Corey. 2019. A Window of Opportunity Trial Using Intratumoral Injection of Glatiramer as an Immune Modulator in Patients with Resectable Head and Neck and Cutaneous Squamous Cell Cancer. Journal for ImmunoTherapy Cancer.
• Al-Jumayli, M, Batool, A, Middiniti, A, Saeed, A, Sun, W, Al-Rajabi, R, Baranda, J, Kumer, S, Schmitt, T, Chidharla, A, Kasi, A. 2019. Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience.. Journal of oncology, 2019, 3293509.
• Dandawate, P, Kaushik, G, Ghosh, C, Standing, D, Sayed AAA, Choudhury, S, Subramaniam, D, Manzardo, A, Banerjee, T, Santra, S, Ramamoorthy, P, Butler, M, Padhye, S., B, Baranda, J, Kasi, A, Sun, W, Tawfik, O, Coppola, D, Malafa, M, Umar, S, Soares, M., J, Saha, S, Weir, S., J, Dhar, A, Jensen, R., A, Thomas, S., M, Anant, S. 2019. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.. Gastroenterology.